What HoneyNaps does

HoneyNaps Co., Ltd. is a South Korea-based sleep health technology company founded in 2015 that develops AI-powered software and biosignal monitoring systems for sleep disorder diagnosis, patient management, and digital therapeutics. Its core platform, SOMNUM, is an FDA 510(k)-cleared deep learning algorithm with an eXplainable Medical AI (XAI) framework that performs real-time automated analysis of multi-channel polysomnography (PSG) biosignals — EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, and snoring — reducing expert scoring time from 3–4 hours to approximately 5 minutes per study. The portfolio is organized around the SOMNUM brand and includes SOMNUM Pro (clinical-grade AI sleep diagnostics), SOMNUM Cloud (cloud-delivered EDF file analysis launched August 2025), SOMNUM Scanning (FCC-certified non-contact radar-based home sleep monitoring), SOMNUM PAX (integrated central monitoring system), and SOMNUM Medella (a digital therapeutic for insomnia built on digital CBT-I), supported by the broader HoneyCube bio-signal management platform.

The company generates revenue through five complementary streams: enterprise AI software licensing to hospitals and sleep centers on a recurring basis, hardware sales of SOMNUM Scanning sensors, professional services for AI-based re-scoring of PSG data in pharmaceutical and medical device clinical trials, technology licensing to over 60 tier-1 medical device companies globally, and consumer-facing hospitality and corporate wellness packages (e.g., partnerships with InterContinental, Novotel, and GS Group). Go-to-market is hybrid: direct enterprise field sales through its Seoul headquarters and Boston/Cambridge U.S. subsidiary (HoneyNaps USA Inc.), a developing international distributor network, event-driven lead generation at major sleep medicine conferences (SLEEP/AASM, World Sleep Congress), and targeted OEM/white-label licensing. Customers include university hospitals in Korea and the U.S. (Soonchunhyang Bucheon, Seoul Asan, Nevada, Seattle, Miami), pharmaceutical partners for clinical trial collaboration, luxury hotel groups, and corporate wellness programs.

HoneyNaps is pre-IPO, venture-backed, and pursuing a KOSDAQ listing with Korea Investment & Securities as lead underwriter, with a goal of becoming South Korea's first publicly listed sleep tech company. Total disclosed funding is approximately $16.2 million across a 2019 seed (~$700K from TS Investment), a 2021 Series A (~$3.9M), and a February/May 2024 Series B (~$11.6M / 15 billion KRW led by iM Investment Partners, KDB Industrial Bank, QUAD Investment Management, and Albatross Investment). Headcount is in the 11–50 range, and the company holds FDA 510(k), ISO 13485, ISO/IEC 27001, HIPAA, and FCC certifications.

Name

HoneyNaps

Legal name

HoneyNaps Co., Ltd.

Website

https://honeynaps.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

HoneyNaps develops FDA-cleared AI software (SOMNUM) that automates polysomnography analysis for hospitals, sleep centers, pharmaceutical clinical trials, and consumer wellness applications across Korea, the U.S., and other international markets.

Ownership category

akta.pro rank

Product category

AI Sleep Diagnostics Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (6215)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• AI sleep diagnostics
• Polysomnography analysis software
• Digital therapeutics insomnia
• Bio-signal monitoring platform
• Clinical trial PSG services

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Software Licensing: HoneyNaps licenses its FDA-cleared SOMNUM AI software to hospitals, sleep centers, and healthcare institutions for automated PSG analysis. Revenue is generated through software deployment contracts with healthcare providers.
2. Hardware and Device Sales: Sale of SOMNUM Scanning non-contact sleep monitoring devices and sensors for home use and clinical settings. FCC certified for the U.S. market.
3. Clinical Trial Services: HoneyNaps provides AI-based re-scoring services to pharmaceutical and medical device companies conducting clinical trials, significantly reducing trial timelines and costs by automating PSG data analysis.
4. Technology Licensing: The company receives licensing inquiries from over 60 tier-1 medical device companies and is expanding licensing agreements globally. Pursuing partnerships with pharmaceutical companies for drug development support.
5. Hospitality Sleep Solutions: Partnerships with hotels (Novotel, InterContinental, Imperial Palace) providing sleep analysis packages and wellness solutions for hotel guests.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

HoneyNaps develops and sells the SOMNUM family of FDA 510(k)-cleared AI sleep disorder diagnosis software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring), reducing manual scoring from 3-4 hours to approximately 5 minutes. The platform is licensed to hospitals, sleep centers, and pharmaceutical companies for clinical use and clinical trial re-scoring, and is complemented by non-contact SOMNUM Scanning hardware, cloud-based SOMNUM Cloud, and SOMNUM Medella digital therapeutics for insomnia.

Product overview

HoneyNaps offers a comprehensive AI-powered sleep healthcare platform centered on SOMNUM technology. The core SOMNUM product is an FDA-cleared AI sleep disorder diagnosis algorithm that analyzes multi-channel biosignals in real-time. The platform includes specialized modules: SOMNUM Scanning (non-contact home sleep monitoring), SOMNUM Cloud (cloud-based PSG analysis), SOMNUM PAX (central monitoring system), and SOMNUM Medella (insomnia digital therapeutic). Additional offerings include HoneyCube bio-signal monitoring platform and newborn sleep monitoring solutions. The company also provides AI-based clinical trial services for pharmaceutical and medical device companies. SOMNUM integrates international medical standards including HL7 and DICOM interfaces.

Differentiator

Problem solved

Functional benefit

Brands

• SOMNUM: FDA-cleared AI sleep disorder diagnosis software that analyzes multi-channel/time-series biosignal data from polysomnography in real time, reducing analysis time from 3-4 hours to approximately 5 minutes. Based on eXplainable Medical AI (XAI) technology.
• SOMNUM Cloud
• SOMNUM Scanning
• SOMNUM PAX
• SOMNUM Medella
• HoneyCube

Products and services

• SOMNUM AI Sleep Diagnosis Software FDA 510(k)-cleared deep learning AI software that performs real-time automated analysis of multi-channel polysomnography biosignals (EEG, EOG, EMG, ECG, airflow, oxygen saturation, posture, snoring) to assist diagnosis of sleep disorders including sleep staging, respiratory events, arousal events, and leg movements. Designed for hospitals, sleep centers, and pharmaceutical clinical trial use.
• SOMNUM Scanning FCC-certified non-contact sleep analysis and coaching hardware that uses radar/sensor technology to collect sleep data at home without electrode attachment. Validated through clinical trials with over 2,000 participants and targeted at home sleep testing.
• SOMNUM Cloud Cloud-based AI platform that enables users to upload EDF files from PSG systems directly to the cloud for automated AI analysis without requiring local software installation. HIPAA compliance assessment completed for U.S. deployment.
• SOMNUM PAX All-in-one integrated central monitoring system that combines SOMNUM PSG AI diagnostic software with sleep monitoring capabilities for hospital and clinical environments.
• SOMNUM Medella Second-generation digital therapeutic device for insomnia based on digital Sleep Improvement Behavior Therapy for Insomnia (dSIBT-I), combining objective patient sleep analysis from non-contact sensors with AI-personalized cognitive behavioral therapy modules.
• SOMNUM Pro Professional-grade AI sleep diagnostic solution designed for clinical settings and hospital sleep centers, distributed under signed international contracts at World Sleep 2025.
• HoneyCube Intelligent bio-signal monitoring platform that collects and analyzes body temperature, heart rate, breathing, and movement during sleep to detect abnormal symptoms early. Supports international standards including HL7, DICOM, and ISO interfaces for hospital, hotel, and individual customer deployments.
• AI Clinical Trial PSG Re-Scoring Service Service offering for pharmaceutical and medical device companies using SOMNUM AI to re-score PSG data from clinical trials, reducing trial timelines and costs while improving scoring consistency across sites.

Quantifiable outcome

• Analysis time reduced from 3-4 hours to approximately 5 minutes per PSG study
• +5 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered exploratory, core and minor.

• Major German AutomakerexploratoryStrategic or Co-development Partner · 1 May 2024Preliminary technical discussions with major German car manufacturer for integration of AI sleep analysis into automotive healthcare solutions. Focus on advanced sensing for driver and passenger monitoring. Presented 'Healthy Sleep in Cars' concept.
• Soonchunhyang University Bucheon HospitalcoreStrategic or Co-development Partner · 1 August 2023Research collaboration with Professor Ji Ho Choi's team for AI sleep biosignal interpretation system development. SOMNUM developed in partnership with hospital sleep medicine specialists. Professor Choi holds certifications from AASM, ESRS, and WSS.
• Whan In PharmcoreStrategic or Co-development Partner · 1 May 2023MOU signed for development of digital therapeutic solutions for insomnia. Collaboration based on mutual trust to drive digital therapeutics development and establish business model integrated with pharmaceutical industry.
• Seoul Asan HospitalcoreStrategic or Co-development Partner · 1 May 2023Clinical trial partnership with Professor Seokhoon Jeong's team for second-generation insomnia digital therapeutic device (dSIBT-I). Randomized prospective double-blind trial evaluated effectiveness and safety for insomnia treatment.
• University of Washington / Harborview Medical CenterminorStrategic or Co-development Partner · 1 January 2023Collaborative partnership for executive education program with GS Group, including facility visits and discussions on U.S. bio/medical research trends and dementia/cardiovascular disease research based on sleep data.
• GS GroupminorStrategic or Co-development Partner · 1 January 2023Integrated sleep technology into GS Group executive education program for corporate well-being. Conducted sleep analysis for executives and explored sleep market trends and data review.
• KT CorporationcoreStrategic or Co-development Partner · 1 December 2020Business agreement to collaborate on sleep health management AI business platform. Combined HoneyNaps' sleep bio-signal monitoring with KT GiGA Genie solution for personalized healthcare services. Also promoted technology development cooperation using HoneyNaps' X.AI core technology with KT's AI/BigData business endeavors.
• Megazone CloudcoreTechnology or Integration · 1 November 2020Joint development of 'sleep diagnosis' cloud platform using big data. Megazone Cloud provides cloud infrastructure expertise while HoneyNaps contributes AI technology and clinical database assets. Platform enables transfer of sleep bio-signal data to hospitals, hotels, and individual customers.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Oura: Consumer wearable with sleep tracking and increasingly clinical-grade health insights through partnerships. Adjacent competitor for consumer sleep monitoring and predictive health analytics based on biosignal data.
• Dreem: Consumer-grade sleep monitoring headband with AI-driven sleep staging, comparable in technology approach (EEG-based biosignal analysis with deep learning) to HoneyNaps' PSG AI platform, though targeting consumer rather than clinical market.
• Big Health (Sleepio): Digital therapeutic for insomnia (Sleepio) using CBT-I, comparable to HoneyNaps' SOMNUM Medella DTx. Both target the same insomnia treatment market with software-based delivery of CBT-I.
• CleveMed: U.S.-based sleep diagnostics company providing home sleep testing devices and cloud-based scoring services. Comparable in serving sleep centers and clinical research with PSG/HST solutions.

Direct peers

• EnsoData: AI-powered sleep scoring and analysis platform, the only other U.S.-headquartered company with FDA clearance for AI sleep scoring (alongside Cerebra Medical and HoneyNaps). Directly competes with HoneyNaps in automated PSG analysis for hospitals and clinical trials.
• Compumedics: Australian-listed company manufacturing PSG hardware and analysis software (ProFusion, ProfSleep). Comparable as a vertically integrated sleep diagnostics provider with hospital customers globally.
• Nox Medical: Icelandic PSG hardware and software company offering Nox A1 PSG systems and clinical software. Comparable as an integrated sleep diagnostics provider competing in the same hospital sleep center procurement decisions.
• Cerebra Medical: Canadian AI sleep diagnostic company that, along with EnsoData and HoneyNaps, is one of only three companies globally with FDA clearance for AI sleep scoring. Directly comparable in technology, regulatory positioning, and clinical use case.

Broad incumbents

• ResMed: Global leader in sleep apnea therapy and connected health, with Nox Medical acquisition (2023) expanding into PSG diagnostics. Competes broadly across the sleep healthcare value chain including diagnostics, therapy, and software.
• Philips Respironics: Major incumbent in sleep diagnostics and therapy with Alice PSG systems and Sleepware G3 software. Competes as a broader portfolio vendor with significantly larger sales coverage, but HoneyNaps' AI-first approach targets the same sleep center budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HoneyNaps